Girentuximab

From WikiMD.org
Jump to navigation Jump to search

Girentuximab

Girentuximab (pronounced: gi-ren-tux-i-mab) is a monoclonal antibody designed for the treatment of renal cell carcinoma, a type of kidney cancer. It is a type of immunotherapy that targets carbonic anhydrase IX (CAIX), a protein that is overexpressed in renal cell carcinoma.

Etymology

The name "Girentuximab" follows the World Health Organization's guidelines for the nomenclature of monoclonal antibodies. The prefix "Giren-" is randomly assigned, "-tuxi-" indicates that it targets tumors, and "-mab" denotes that it is a monoclonal antibody.

Mechanism of Action

Girentuximab works by binding to the CAIX protein on the surface of renal cell carcinoma cells. This binding triggers an immune response that leads to the destruction of the cancer cells.

Related Terms

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski